CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients

• Published in: International journal of molecular sciences Vol. 25; no. 13; p. 7412
• Main Authors: Nekić, Jasna, Stanković Matić, Ivana, Rački, Valentino, Janko Labinac, Dolores, Vuletić, Vladimira, Kapović, Miljenko, Ristić, Smiljana, Peterlin, Borut, Starčević Čizmarević, Nada
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 05.07.2024
• Subjects: Adult; Biomarkers; CCR5 Δ32; Chemokines; Croatia; CTLA-4 +49 A/G; CTLA-4 Antigen - genetics; Cytokines; Disease; Female; Females; Gene Frequency; Genes; Genotype; Genotype & phenotype; Humans; IFN-β; Interferon; Interferon-beta - therapeutic use; Lymphocytes; Male; Middle Aged; Multiple sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis - genetics; Patients; polymorphism; Polymorphism, Single Nucleotide; Proteins; Receptors, CCR5 - genetics; Regulatory approval; Slovenia; Treatment Outcome; treatment response; Slovenia; Croatia; United States > US; CCR5 Δ32; polymorphism; IFN-β; multiple sclerosis; treatment response; CTLA-4 +49 A/G
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25137412

The aim of the present study was to investigate the impact of CCR5 Δ32 and CTLA-4 polymorphisms on the response to IFN-β treatment in our cohort of MS patients from Croatia and Slovenia. Genomic DNA was obtained from 295 MS patients (230 female; 65 male) classified as responders ( = 173) and non-responders ( = 122) based on clinical criteria for treatment efficacy. Genotyping was performed via PCR/PCR-RFLP. No significant differences in the genotype/allele frequencies of CCR5Δ32 and CTLA-4 +49 A/G were detected between male responders and non-responders. A significantly higher prevalence ( = 0.039) of the CTLA-4 +49 AA genotype was found in female responders (42.1%) compared to non-responders (28.9%). Using multiple forward regression analysis, the CTLA-4 +49 AA genotype significantly predicted a positive response to IFN-β therapy in females ( = 0.011) and contributed to 4.5% of response variability. Furthermore, the combined presence of the CCR5Δ32 wtwt/CTLA-4 +49 AA genotype significantly predicted a positive response to treatment in females ( = 0.025). The age at disease onset, pretreatment relapse rate, and baseline EDSS score were not reliable predictors of treatment response in MS patients. Our results indicate that the presence of the CCR5Δ32 polymorphism was not associated with the response to IFN-β treatment, whereas the CTLA-4 +49 polymorphism showed a positive correlation with an optimal response in female patients.